186 related articles for article (PubMed ID: 36932175)
1. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.
Kawabata S; Gills JJ; Mercado-Matos JR; Lopiccolo J; Wilson W; Hollander MC; Dennis PA
Cell Death Dis; 2012 Jul; 3(7):e353. PubMed ID: 22825471
[TBL] [Abstract][Full Text] [Related]
4. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
5. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
7. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
8. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
9. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).
Driessen C; Kraus M; Joerger M; Rosing H; Bader J; Hitz F; Berset C; Xyrafas A; Hawle H; Berthod G; Overkleeft HS; Sessa C; Huitema A; Pabst T; von Moos R; Hess D; Mey UJ
Haematologica; 2016 Mar; 101(3):346-55. PubMed ID: 26659919
[TBL] [Abstract][Full Text] [Related]
11. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
12. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
13. NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Yang Y; Ikezoe T; Nishioka C; Bandobashi K; Takeuchi T; Adachi Y; Kobayashi M; Takeuchi S; Koeffler HP; Taguchi H
Br J Cancer; 2006 Dec; 95(12):1653-62. PubMed ID: 17133272
[TBL] [Abstract][Full Text] [Related]
14. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
15. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
16. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
17. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.
Kraus M; Bader J; Overkleeft H; Driessen C
Blood Cancer J; 2013 Mar; 3(3):e103. PubMed ID: 23454896
[TBL] [Abstract][Full Text] [Related]
18. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
19. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
Li C; Hu J; Li W; Song G; Shen J
Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
[TBL] [Abstract][Full Text] [Related]
20. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Hideshima T; Qi J; Paranal RM; Tang W; Greenberg E; West N; Colling ME; Estiu G; Mazitschek R; Perry JA; Ohguchi H; Cottini F; Mimura N; Görgün G; Tai YT; Richardson PG; Carrasco RD; Wiest O; Schreiber SL; Anderson KC; Bradner JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13162-13167. PubMed ID: 27799547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
